Inside informationEnglish
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 18/02/2025, 07:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 118991_20250218